Company news

Actinogen Medical Limited news in 2025

Actinogen Medical Limited's news releases, calls and decks from 2025, newest first.

View company

Final, 247th participant randomized and commences treatment in Actinogen’s XanaMIA pivotal phase 2b/3 Alzheimer’s trial

December 18, 2025

ACW XanaMIA trial fully enrolled with 246th participant

December 17, 2025

ACW positive XanaMIA Data Monitoring Committee meeting

November 12, 2025

ACW September 2025 quarterly activity report & Appendix 4C

October 22, 2025

ACW confirms eligibility for further $1.9m RDTI

October 20, 2025

ACW achieves early screening closure for XanaMIA trial

October 19, 2025

ACW receives initial $5.5m R&D tax incentive rebate

October 14, 2025

Actinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem for Alzheimer’s disease

September 15, 2025

ACW successful FDA meeting on Alzheimers program

September 14, 2025

Actinogen trial using intended commercial Xanamem tablet formulation confirms target exposures in fed and fasted states

August 27, 2025

ACW pharmacokinetics trial success

August 26, 2025

ACW FY2025 results - accelerating Alzheimers pivotal trial

August 25, 2025

ACW Appendix 4E and 2025 annual report

August 25, 2025

Actinogen June 2025 quarterly activity report & Appendix 4C

July 29, 2025

A novel oral treatment for Alzheimer's: Actinogen's pivotal trial currently recruiting participants in the US

July 22, 2025

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer's disease trial and interim analysis timeline

June 30, 2025

ACW accesses up to $13.8m in non-dilutive R&D tax funding

June 29, 2025

ACW 100th AD trial participant & interim analysis timeline

June 29, 2025

Actinogen provides pivotal Alzheimer’s trial enrolment update and other business news

April 30, 2025

Actinogen March 2025 quarterly activity report & Appendix 4C

April 29, 2025

ACW conducts Type C meeting with FDA regarding depression

March 27, 2025

ACW HY25 results Advancing to latestage clinical development

February 24, 2025

Peer-reviewed clinpharm manuscript published

February 6, 2025

ACW December 2024 quarterly activity report & Appendix 4C

January 28, 2025

Decks in 2025